Products

Hot Sale 99% Berberine Chloride CAS 141433 -60-5

China Hot Sale 99% Berberine Chloride CAS 141433-60-5, Find details about China 141433-60-5, 99% Berberine Chloride from Hot Sale 99% Berberine Chloride CAS 141433-60-5

Trademark
ty
Transport Package
Custom
Specification
25kg/bag
Origin
China
Trademark
ty
Transport Package
Custom
Specification
25kg/bag
Origin
China

Product Name: BERBERINE CHLORIDE
Synonyms: Berberine (berberine hydrochloride);Berberine chloride hydrate 97%;9,10-DiMethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-iuM chloride hydrate;Berberine chloride hydrate technical, >=90% (AT);Benzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium,5,6-dihydro-9,10-dimethoxy-, chloride, hydrate (1:1:);LABOTEST-BB LT00440956;CI 75160;BERBERIN HCL
CAS: 141433-60-5
MF: C20H18ClNO4
MW: 371.81
EINECS: 211-195-9Hot Sale 99% Berberine Chloride CAS 141433-60-5Hot Sale 99% Berberine Chloride CAS 141433-60-5Lidocaine

Lidocaine structure
Factory Direct Sales Top Quality CAS 137-58-6 99.99% Pure Lidocaine Powder From Wuhan Mulei
Common NameLidocaine
CAS Number137-58-6Molecular Weight234.337
Density1.0±0.1 g/cm3Boiling Point372.7±52.0 °C at 760 mmHg
Molecular FormulaC14H22N2OMelting Point66-69°C
MSDSChineseUSAFlash Point179.2±30.7 °C
Symbol 
GHS07		Signal WordWarning

 Use of Lidocaine

 
Lidocaine, an amide local anesthetic, has anti-inflammatory properties in vitro and in vivo, possibly due to an attenuation of pro-inflammatory cytokines, intracellular adhesion molecule-1 (ICAM-1), and reduction of neutrophils influx.Target: Lidocaine is a common local anesthetic and antiarrhythmic drug. Lidocaine is used topically to relieve itching, burning and pain from skin inflammations, injected as a dental anesthetic or as a local anesthetic for minor surgery. Lidocaine, the first amino amide-type local anesthetic, was first synthesized under the name xylocaine by Swedish chemist Nils Lofgren in 1943. His colleague Bengt Lundqvist performed the first injection anesthesia experiments on himself.Lidocaine is approximately 95% metabolized (dealkylated) in the liver by CYP3A4 to the pharmacologically-active metabolites monoethylglycinexylidide (MEGX) and then subsequently to the inactive glycine xylidide. MEGX has a longer half life than lidocaine but also is a less potent sodium channel blocker. The elimination half-life of lidocaine is approximately 90-120 minutes in most patients. This may be prolonged in patients with hepatic impairment (average 343 minutes) or congestive heart failure (average 136 minutes).

You Might Also Like